Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

Inclusion Criteria: * 18 years of age or over * Has enlarged lymph node(s) highly suspicious of lymphoma; or has been diagnosed with lymphoma but is untreated; or has persistent recurrent, or progressive lymphoma * At least one enlarged lymph node that is considered accessible for percutaneous injection by the investigator and that is at least 2 cm in longest dimension. * ECOG performance status of 0-2 (or a Karnofsky performance status of \>50%). * Labs required for enrollment: Absolute neutrophil count \> 1000/mm3, platelet count \> 50,000/mm3, hematocrit \> 25%, creatinine \<3.0 mg/dl, total bilirubin \<4.0 mg/dl, SGOT and SGPT less than five times the institutional upper limits of normal. Exclusion Criteria: * Lymphoma patients in which the delay of surgery until the lymph node resection date or other factors associated with the study are not feasible. * Patients with central nervous system disease. * Any therapy that is potentially immunosuppressive or has anticancer activity in the 4 weeks prior to device microinjection. * Patients with active fungal, viral, or bacterial infections * Pregnant women. * Inability to give informed consent.